We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Eli Lilly and Company (Lilly) has signed a definitive agreement to acquire all outstanding shares of Dermira, a biopharmaceutical company focused on medical dermatology, at a purchase price
US-based precision therapy provider Blueprint Medicines has received the US Food and Drug Administration (FDA) approval for AYVAKIT (avapritinib) to treat a type of gastrointestinal cancer. The FDA
Eli Lilly and Company (Lilly) in partnership with Strateos, a SaaS-based biotechnology company, has opened a new robotic cloud laboratory in San Diego, California, to advance the drug
SAB Biotherapeutics, a clinical-stage biopharmaceutical company, has signed various partnership and option agreements with CSL Behring, a developer and manufacturer of protein-based therapies. The company said that the
Merck has received the US Food and Drug Administration (FDA) approval for KEYTRUDA, an anti-PD-1 therapy for non-muscle invasive bladder cancer (NMIBC). The US FDA approval indicated KEYTRUDA
Personalis, a US-based cancer genomics company, has launched the NeXT Dx Test, designed to help oncologists in identifying cancer therapies and clinical trial options. The company claimed that
US-based clinical-stage biopharmaceutical company Cerebral Therapeutics has secured $35m in a Series B financing round, led by RA Capital Management. The company revealed that the new investor Perceptive
Merck’s biopharmaceutical business, EMD Serono, and Pfizer announced the positive results of the Phase III JAVELIN Bladder 100 trial of BAVENCIO (avelumab) for the treatment of urothelial carcinoma
AstraZeneca has received the US Food and Drug Administration (FDA) acceptance for its supplemental New Drug Application (sNDA), and was granted Priority Review for its Farxiga (dapagliflozin). Farxiga
US-based biopharmaceutical company Leap Therapeutics has signed an exclusive option and license agreement with BeiGene, a cancer therapeutics provider, for the clinical development and commercialisation of DKN-01, in